Tom 19, Nr 1-2 (2024)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2024-12-11
Przyłóżkowe testy do oznaczenia wysokoczułej troponiny sercowej. Gdzie jesteśmy?
Kardiol Inwazyjna 2024;19(1-2).
Streszczenie
Praca we współczesnym oddziale ratunkowego nie byłaby możliwa bez wykonywanych w centralnym laboratorium wysokoczułych testów dla troponiny sercowej (hs-cTn, high-sensitivity cardiac troponins). Umożliwiają one podjęcie szybkiej i precyzyjnej decyzji dotyczącej pacjentów z podejrzeniem ostrego zespołu wieńcowego. Od niedawna dostępne są również testy przyłóżkowe dla oznaczenia poziomu troponiny (POCT, point-of-care testing). To nowe narzędzie diagnostyczne stwarza nadzieję na szybszą diagnostykę pacjentów w oddziałach ratunkowych i usprawnienie przedszpitalnego postępowania w przypadku podejrzenia ostrego zespołu wieńcowego. POCT mogą mieć także zastosowanie w innych sytuacjach klinicznych, w których ważny jest czas do podjęcia decyzji. W niniejszej pracy przedstawiono obecny stan wiedzy na temat dostępnych testów POCT hs-cTn, korzyści płynących z ich stosowania w konkretnych sytuacjach klinicznych jak również problemy związane z wdrożeniem hs-cTn POCT do rutynowej praktyki klinicznej.
Słowa kluczowe: Badanie przyłóżkowewysokoczuła troponina sercowaostry zespół wieńcowy
Referencje
- Thygesen K, Alpert JS, Jaffe AS, et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction, ESC Scientific Document Group, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018; 72(18): 2231–2264.
- Sandoval Y, Apple FS, Saenger AK, et al. 99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. Clin Chem. 2020; 66(9): 1167–1180.
- Wu AHB, Christenson RH, Greene DN, et al. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2018; 64(4): 645–655.
- Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009; 361(9): 858–867.
- Byrne RA, Rossello X, Coughlan JJ, et al. ESC Scientific Document Group, ESC Scientific Document Group, ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720–3826.
- Collinson P, Aakre KM, Saenger A, et al. Cardiac troponin measurement at the point of care: educational recommendations on analytical and clinical aspects by the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (IFCC C-CB). Clin Chem Lab Med. 2023; 61(6): 989–998.
- High-Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer. IFCC Committee on Clinical Applications of Cardiac Bio- Markers (C-CB) v052022. . https://ifcc. org/ifcc-education-division/emd-committees/committee- on-clinical-applications-of-cardiac-bio-markers-c-cb/ biomarkers-reference-tables/.
- Sun BC, Hsia RY, Weiss RE, et al. Effect of emergency department crowding on outcomes of admitted patients. Ann Emerg Med. 2013; 61(6): 605–611.e6.
- Jones S, Moulton C, Swift S, et al. Association between delays to patient admission from the emergency department and all-cause 30-day mortality. Emerg Med J. 2022; 39(3): 168–173.
- Boeddinghaus J, Nestelberger T, Koechlin L, et al. APACE Investigators. Early Diagnosis of Myocardial Infarction With Point-of-Care High-Sensitivity Cardiac Troponin I. J Am Coll Cardiol. 2020; 75(10): 1111–1124.
- Apple FS, Schulz K, Schmidt CW, et al. Determination of sex-specific 99th percentile upper reference limits for a point of care high sensitivity cardiac troponin I assay. Clin Chem Lab Med. 2021; 59(9): 1574–1578.
- Pickering JW, Young JM, George PM, et al. Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction. JAMA Cardiol. 2018; 3(11): 1108–1112.
- Ryan RJ, Lindsell CJ, Hollander JE, et al. A multicenter randomized controlled trial comparing central laboratory and point-of-care cardiac marker testing strategies: the Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) trial. Ann Emerg Med. 2009; 53(3): 321–328.
- Bradburn M, Goodacre SW, Fitzgerald P, et al. RATPAC Research Team. Interhospital variation in the RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Emerg Med J. 2012; 29(3): 233–238.
- Loten C, Attia J, Hullick C, et al. Point of care troponin decreases time in the emergency department for patients with possible acute coronary syndrome: a randomised controlled trial. Emerg Med J. 2010; 27(3): 194–198.
- Goyder C, Tan PS, Verbakel J, et al. Impact of point-of-care panel tests in ambulatory care: a systematic review and meta-analysis. BMJ Open. 2020; 10(2): e032132.
- Ezekowitz JA, Welsh RC, Weiss D, et al. Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). J Am Heart Assoc. 2015; 4(12).
- Than M, Cullen L, Reid C, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. The Lancet. 2011; 377(9771): 1077–1084.
- Goodacre SW, Bradburn M, Cross E, et al. RATPAC Research Team. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart. 2011; 97(3): 190–196.
- Body R, Almashali M, Morris N, et al. Diagnostic accuracy of the T-MACS decision aid with a contemporary point-of-care troponin assay. Heart. 2019; 105(10): 768–774.
- Pickering JW, Than MP, Cullen L, et al. Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis. Ann Intern Med. 2017; 166(10): 715–724.
- Koechlin L, Boeddinghaus J, Lopez-Ayala P, et al. APACE Investigators. Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay. J Am Coll Cardiol. 2024; 84(8): 726–740.
- Thulin V, et al. WESTCOR-POC - Point of care versus centralised high-sensitivity cardiac troponin in the emergency department. Presetation at European Society of Cardiology. 2024.
- Tolsma RT, Fokkert MJ, van Dongen DN, et al. Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study. Eur Heart J Acute Cardiovasc Care. 2022; 11(2): 160–169.
- Christenson RH, Frenk LDS, de Graaf HJ, et al. Point-of-Care: Roadmap for Analytical Characterization and Validation of a High-Sensitivity Cardiac Troponin I Assay in Plasma and Whole Blood Matrices. J Appl Lab Med. 2022; 7(4): 971–988.
- Halvorsen S, Mehilli J, Choorapoikayil S, et al. ESC Scientific Document Group, ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022; 43(39): 3826–3924.
- Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43: 4229–361.
- Lyngbakken MN, Skranes JB, de Lemos JA, et al. Gender, High-Sensitivity Troponin I, and the Risk of Cardiovascular Events (from the Nord-Trøndelag Health Study). Am J Cardiol. 2016; 118(6): 816–821.
- de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010; 304(22): 2503–2512.
